Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Monsanto strikes two gene editing deals

by Melody M. Bomgardner
July 11, 2016 | A version of this story appeared in Volume 94, Issue 28

Discovering and developing a new crop trait can take seven years and cost more than $50 million. Monsanto has inked two deals to license gene editing technologies that it believes will provide cheaper and faster ways to deliver crop improvements. A deal with the Israeli firm TargetGene Biotechnologies will give Monsanto researchers access to RNA-guided gene-editing techniques. Monsanto also invested in the start-up. Separately, Monsanto has begun a three-year research project with Germany’s Nomad Bioscience to help Nomad develop its transient protein expression gene-editing technology. The agreement gives Monsanto the right to use Nomad’s technology for its own research, plus an option to license it for agricultural products. “Gene-editing technologies offer a way for scientists to develop site-directed integration of specific genes as well as the opportunity to enhance beneficial or remove undesired plant characteristics,” Monsanto says.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.